Dashboard
Manage Tickers

ABCL AbCellera Biologics Inc.

Nasdaq abcellera.com


$ 4.13 $ 0.12 (3.07 %)    

Monday, 10-Nov-2025 17:59:49 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 623.30 $ 13.49 (2.21 %)
DIA $ 473.69 $ 3.96 (0.84 %)
SPY $ 681.32 $ 10.47 (1.56 %)
TLT $ 89.42 $ -0.02 (-0.02 %)
GLD $ 379.01 $ 10.07 (2.73 %)
$ 4.03
$ 4.17
$ 4.04 x 4
$ 4.14 x 1
$ 3.80 - $ 4.19
$ 1.89 - $ 6.52
7,152,670
na
1.17B
$ 1.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-27-2025 12-31-2024 10-K
5 11-04-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-20-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-21-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 02-25-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-13-2021 06-30-2021 10-Q
19 05-14-2021 03-31-2021 10-Q
20 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ai-stocks-extend-selloff-nasdaq-100-eyes-worst-week-since-april-whats-moving-markets-friday
AI Stocks Extend Selloff, Nasdaq 100 Eyes ...
11/07/2025 17:45:12

Risk-off sentiment dominated Wall Street on Friday, with selling pressure in AI-linked names intensifying and pushing technolog...

leerink-partners-downgrades-abcellera-biologics-to-market-perform-announces-4-price-target
Leerink Partners Downgrades AbCellera Biol...
11/07/2025 12:22:57

Leerink Partners analyst Faisal Khurshid downgrades AbCellera Biologics (NASDAQ:ABCL) from Outperform to Market Perform and ...

abcellera-biologics-q3-eps-019-misses-017-estimate-sales-8955m-beat-5909m-estimate
AbCellera Biologics Q3 EPS $(0.19) Misses ...
11/06/2025 21:09:14

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of...

ai-stocks-slide-again-bitcoin-dips-near-100000-whats-moving-markets-thursday
AI Stocks Slide Again, Bitcoin Dips Near $...
11/06/2025 17:45:11

After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading...

earnings-scheduled-for-november-6-2025
Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

stock-market-today-dow-futures-slip-sp-500-rises-amid-mixed-tradeberkshire-occidental-fermi-in-focus
Stock Market Today: Dow Futures Slip, S&P ...
10/02/2025 09:50:44

U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices w...

why-did-abcelleras-stock-jump-over-7-after-hours
Why Did AbCellera's Stock Jump Over 7% Aft...
10/02/2025 06:15:08

AbCellera's stock rose 7.72% in after-hours trading following an 18.49% gain during regular trading, with a strong performa...

abcellera-doses-first-participants-in-phase-1-clinical-trial-of-abcl575-for-treatment-of-moderate-to-severe-atopic-dermatitis
AbCellera Doses First Participants In Phas...
08/27/2025 13:11:05

Core News & Articles
10 Health Care Stocks With Whale Alerts In...
08/18/2025 17:35:28

expert-outlook-abcellera-biologics-through-the-eyes-of-4-analysts
Expert Outlook: AbCellera Biologics Throug...
08/08/2025 18:02:05

stifel-maintains-buy-on-abcellera-biologics-lowers-price-target-to-7
Stifel Maintains Buy on AbCellera Biologic...
08/08/2025 13:41:00

Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and lowers the price target from $8 to $7.

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
08/08/2025 12:08:44

abcellera-initiates-dosing-of-participants-in-a-phase-1-clinical-trial-of-abcl635-co-initiated-a-phase-1-clinical-trial-of-abcl575-which-is-being-developed-for-the-treatment-of-moderate-to-severe-atopic-dermatitis
AbCellera Initiates Dosing Of Participants...
08/07/2025 21:11:57

abcellera-biologics-q2-eps-012-beats-015-estimate-sales-17084m-beat-5824m-estimate
AbCellera Biologics Q2 EPS $(0.12) Beats $...
08/07/2025 20:33:07

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

galaxy-digital-blaize-holdings-verizon-and-other-big-stocks-moving-higher-on-monday
Galaxy Digital, Blaize Holdings, Verizon A...
07/21/2025 14:16:31

keybanc-maintains-overweight-on-abcellera-biologics-raises-price-target-to-10
Keybanc Maintains Overweight on AbCellera ...
07/14/2025 12:06:40

Keybanc analyst Scott Schoenhaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target f...

leerink-partners-assumes-abcellera-biologics-at-outperform-announces-price-target-of-5
Leerink Partners Assumes AbCellera Biologi...
07/07/2025 12:39:13

Leerink Partners analyst Faisal Khurshid assumes AbCellera Biologics (NASDAQ:ABCL) with a Outperform rating and announces Pr...

health-canada-grants-no-objection-letter-for-abcelleras-abcl575-advancing-investigational-ox40l-antibody-for-ad-treatment
Health Canada Grants No Objection Letter f...
05/30/2025 17:02:48

ABCL575 is an Fc-silenced, half-life extended investigational antibody medicine that is being developed for the treatment of at...

truist-securities-maintains-buy-on-abcellera-biologics-lowers-price-target-to-10
Truist Securities Maintains Buy on AbCelle...
05/16/2025 17:40:41

Truist Securities analyst Robyn Karnauskas maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and lowers the price targe...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION